Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CANFOUR: targeting IL1RAP for NSCLC or pancreatic cancer

Ahmad Awada, MD, PhD, of the Jules Bordet Cancer Institute, Brussels, Belgium, discusses the CANFOUR trial (NCT03267316) investigating CAN04, a monoclonal antibody targeting IL1RAP for patients with non-small cell lung cancer (NSCLC) or pancreatic cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.